SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to a mix of positive news and ongoing debates about its valuation and future potential. Recent advancements, like achieving its quantum performance milestone early, are fueling optimism, while discussions around share dilutions and comparisons to other tech sectors contribute to market volatility. The community is actively debating the impact of these factors on the stock's short-term and long-term prospects, with some anticipating a short squeeze and others expressing concern about overvaluation.

abrdn ETF - abrdn Physical Platinum Shares ETF

PPLT is trending due to bullish sentiment and unusual options activity, with traders anticipating a potential breakout. Community members are actively discussing market manipulation, supply deficits, and platinum's historical undervaluation compared to gold. Some analysts suggest that a global hydrogen powerplant buildout will cause platinum to surge and that with the Fed cutting rates, it will explode along with gold and silver.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

UPST is trending as investors debate its potential amid fluctuating interest rates and a high short interest. While some community members anticipate a short squeeze and highlight positive technical indicators like a doji candle, others express concern over recent price action and question its performance relative to other fintech stocks. The stock's sensitivity to rate cut news and overall market conditions is a key point of discussion.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending following the announcement of a recent private placement of approximately $44 million, sparking significant after-hours movement. The community is actively discussing the potential for continued momentum, while some are analyzing the details of the deal, particularly the warrants involved, and anticipating potential dilution. Others point to the tight float and insider holdings as a catalyst for further price action.

Aventus Network

Aventus Network ($AVT.X) is trending, with community members highlighting its strong chart setup and bullish indicators for potential breakout; traders are closely watching the volume. The token's low market cap and integration with Polkadot, along with real-world partnerships with Vodafone and Heathrow Airport, are sparking interest as well as Coinbase listing hype. Some believe it is undervalued with significant upside.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors discuss the potential of Deramiocel, particularly its impact on cardiomyopathy in Duchenne Muscular Dystrophy (DMD) patients, following a regulatory update. Community members are debating the significance of PUL and LVEF endpoints and potential label expansion, while emphasizing the importance of upcoming HOPE-3 data. Bulls express confidence in the drug's efficacy and financial standing, while bears point to dilution concerns and regulatory hurdles.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending after announcing positive Phase 2 trial data for its skin drug, leading to speculation about a potential buyout and future gains, though some express concern about an upcoming share offering. The community is actively discussing the drug's efficacy, comparing it to competitors, and debating its potential market value. Some traders are trying to navigate overnight trading restrictions and the possibility of shorting the stock.

SuperCom Ltd. engages in the provision of traditional and digital identity solutions. It offers identification, tracking, and security products to government, private and public organization. It operates through the following divisions: e-Gov, Internet of Things (IoT), and Cyber Security. The e-Gov division provides solutions for traditional and biometrics enrollment, personalization, issuance and border control services. The IoT division products and services reliably identify, track, and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles, and monitored objects. The Cyber Security division is involved in the comprehensive solutions to protect the organization's sensitive data residing on servers, laptops, and detachable devices. The company was founded by Jack Hasan and Eli Rozen on July 4, 1988 and is headquartered in Tel Aviv, Israel.

SuperCom Ltd

SuperCom (SPCB) is trending due to community excitement around potential ICE contracts and recent contract wins, suggesting significant growth potential in the electronic monitoring sector. The company's small float is fueling speculation of a large price increase if a major contract is secured. Community members are actively discussing valuation, technical analysis, and potential acquisition targets.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXY is trending amid reports of potential asset sales and discussions around its valuation relative to peers like DVN. Community discussions include call option activity and potential LEAPS opportunities, with some focusing on its carbon capture initiatives and Buffett's continued involvement while others express frustration with the company's leadership and performance.

TON (The Open Network) is a general-purpose blockchain that allows developers to build decentralized apps and tokens.

Toncoin

Toncoin is trending as the community discusses recent developments around Telegram integration and potential catalysts, including a large token buyback program and staking operations.  The listing of TON on additional exchanges like Robinhood is also a hot topic.  Traders are evaluating its potential within the broader Web3 ecosystem, particularly regarding its relationship with Telegram's user base.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aileron Therapeutics Announces Rebranding to Rein Therapeutics

Aileron Therapeutics Announces Rebranding to Rein Therapeutics Aileron Therapeutics Announces Rebranding to Rein Therapeutics PR Newswire AUSTIN, Texas, Jan. 10, 2025 Rebrand to Rein Therapeutics is...

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR...

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) Aileron Therapeutics Announces Positive Topline Data...

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma Aileron Therapeutics and Advancium Health Network Announce...

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on...

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) Aileron Therapeutics Completes Enrollment in...

Aileron Therapeutics to Present at the 8th Annual IPF Summit

Aileron Therapeutics to Present at the 8th Annual IPF Summit Aileron Therapeutics to Present at the 8th Annual IPF Summit PR Newswire AUSTIN, Texas, Aug. 19, 2024 AUSTIN, Texas, Aug. 19, 2024...

Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights PR Newswire...

Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference PR Newswire AUSTIN...

Aileron Therapeutics to be Included in the Russell Microcap Index

Aileron Therapeutics to be Included in the Russell Microcap Index Aileron Therapeutics to be Included in the Russell Microcap Index PR Newswire AUSTIN, Texas, July 1, 2024 AUSTIN, Texas, July 1, 2024...

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

ALRN
Aileron Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ALRN News

ALRN Aileron Therapeutics Inc